JOURNAL OF BUON, cilt.22, ss.863-868, 2017 (SCI İndekslerine Giren Dergi)
Purpose: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients.